Kornimate/medical-research-clean huggingface dataset:
precise transcranial magnetic stimulation for post-traumatic stress disorder

Conditions: PTSD

Summary: the purpose of this study is to investigate the efficacy and safety of repetitive transcranial magnetic stimulation under precise localization for post-traumatic stress disorder

participants who meet the entry conditions and sign the informed consent will be divided into two groups. the stimulation target of each participant will be determined according to mri. the test group will receive active transcranial magnetic stimulation for 10 consecutive days, and the control group will receive sham stimulation. symptom severity is assessed by scales and audio and video recordings at baseline, during treatment period and follow-up.blood samples will also be collected from patients prior to treatment and will be analyzed histologically to explore differences in response to the intervention and biological mechanisms in different subgroups of patients.

Eligibility criteria:
inclusion criteria: * the subject, regardless of gender, aged between 18 and 65 years, is admitted to the psychosomatic outpatient department of the first affiliated hospital of air force medical university; * the subject meets the diagnostic criteria of post-traumatic stress disorder in diagnostic and statistical manual of mental disorders-5; * the score of posttraumatic stress disorder checklist for diagnostic and statistical manual of mental disorders-5 \> 33； * the subject can understand and is willing to strictly abide by the clinical trial protocol and signs the informed consent. exclusion criteria: * the subject has serious physical diseases or diseases that may affect the central nervous system (such as tumor, syphilis, etc.); * patients with ptsd who keep stable on their original medication/psychotherapy for more than 3 weeks before the start of the study or who have not taken the relevant therapeutic medication for more than 2 weeks before the start of the study will be included.otherwise they will be excluded; * the subject had previous brain diseases, head trauma, alcoholism, eeg abnormalities, mri evidence of abnormal brain structure, or family history of epilepsy; * the subject has contraindications to mri scanning or transcranial magnetic stimulation treatment, such as metal or electronic instruments (intracranial metal foreign bodies, cochlear implants, cardiac pacemakers, stents and other metal foreign bodies) and space phobia; * the subject has a history of contact with psychoactive substances or other mental diseases; * those at high risk of suicide, or those who have committed suicide or serious self injury and need emergency intervention; * pregnant, breastfeeding or planning pregnancy during the trial; * in the judgment of the investigator, the subject has other conditions that are not suitable for the study.

Keywords: transcranial magnetic stimulation
safety, tolerability, and pharmacokinetics of anti-severe acute respiratory syndrome coronavirus 2 (sars-cov-2) chicken egg antibody (igy) (covid-19)

Conditions: Covid19

Summary: the primary objective of part 1 (single ascending dose) is to assess the safety and tolerability of anti-sars-cov-2 igy when given as single-ascending doses administered intranasally to healthy participants. the primary objective of part 2 (multiple dose) is to assess the safety and tolerability of anti-sars-cov-2 igy when given as multiple doses administered intranasally to healthy participants. a secondary objective is to assess the pharmacokinetics of anti-sars-cov-2 igy when given as multiple doses administered intranasally to healthy participants. safety will be evaluated using adverse event (ae), physical examination (including vital signs), electrocardiogram, and clinical laboratory data. pharmacokinetics will be evaluated by serum anti-sars-cov-2 igy concentration.


Eligibility criteria:
inclusion criteria: * healthy males or non-pregnant, non-lactating females * body weight of at least 50 kg * good state of health (mentally and physically) * must agree to use of highly effective method of contraception exclusion criteria: * received other investigational drug within the last 30 days prior to screening * history of drug or alcohol abuse in the past 2 years (\>21 units of alcohol per week for males and \>14 units of alcohol per week for females) * current smoker / e-smoker * abnormal kidney function * abnormal liver function * positive for hepatitis b or c infection * positive for hiv infection * positive for sars-cov-2 infection * history of egg allergy * abnormal cardiac function
assess the efficacy/safety of intravitreal ranibizumab in patients with vision loss due to choroidal neovascularization.

Conditions: Choroidal Neovascularization (CNV)

Summary: this study was conducted to evaluate the efficacy and safety of 0.5 mg ranibizumab in adult and adolescent patients with visual impairment due to choridal neovascularization (cnv).


Eligibility criteria:
key inclusion criteria: * diagnosis of active cnv secondary to any causes with the cnv or its sequelae affecting the fovea; * bcva must be between ≥ 24 and ≤ 83 letters in the study eye; * visual loss in the study eye should mainly be due to the presence of any eligible types of cnv; key exclusion criteria: * women of child-bearing potential; * active malignancies; * history of stroke less than 6 months prior to screening; * uncontrolled systemic inflammation or infection; * active diabetic retinopathy, active ocular/periocular infectious disease or active severe intra-ocular inflammation; * cnv- conditions with a high likelihood of spontaneous resolution; * history of intravitreal treatment with steroids; * history of laser photocoagulation; * history of intraocular treatment with any anti-angiogenic drugs.

Keywords: vision impairment abnormal growth of blood vessels
hrs9531 injection in obese subjects with heart failure with preserved ejection fraction

Conditions: Heart Failure With Preserved Ejection Fraction

Summary: this was a multicenter, randomized, double-blind, placebo-parallel-controlled phase ii clinical study to evaluate the efficacy and safety of hrs9531 injection compared to placebo in obese subjects with heart failure with preserved ejection fraction. a total of 200 obese subjects with heart failure with preserved ejection fraction would be enrolled. eligible subjects were randomly assigned to either hrs9531 group or placebo group and were treated with hrs9531 injection or placebo, respectively, for 52 weeks.


Eligibility criteria:
inclusion criteria: 1. male or female, age above or equal to 18 years at the time of signing informed consent. 2. body mass index (bmi) greater than or equal to 28.0 kg/m\^2 3. new york heart association (nyha) class ii-iv; 4. left ventricular ejection fraction (lvef) greater than or equal to 45 percentage at screening exclusion criteria: 1. medical history of myocardial infarction, acute decompensated heart failure, heart failure requiring hospitalization or urgent heart failure visit, unstable angina, stroke, or transient ischemic attack within 30 days prior to or at screening; 2. haemoglobin a1c (hba1c) greater than or equal to 11.0% at screening.
pragmatic study of messaging to providers of patients with heart failure in amsterdam umc

Conditions: Heart Failure With Reduced Ejection Fraction

Summary: this is a prospective cohort study, where the investigators aim to investigate the effect of implementation of an electronic nudge alerting clinicians to the prescription of the 4 key pharmacological classes for the treatment of patients with heart failure and reduced ejection fraction (hfref) at the outpatient clinic in the netherlands.


Eligibility criteria:
inclusion criteria: * age \> 18 years * treatment for hfref at the outpatient clinic cardiology. * documented reduced ejection fraction of \<40% based on cardiac ultrasound or cardiac magnetic resonance imaging. exclusion criteria: * opt-out for the use of routine clinical data for research purposes

Keywords: electronic health records electronic nudge guideline directed medical therapy
strategies in patients undergoing repeat af ablation

Conditions: Atrial Fibrillation

Summary: the aim of the proposed research project is to compare the efficacy of three different ablation strategies in patients with atrial fibrillation (af) who are undergoing their first repeat catheter ablation for recurrent af.

reconnection of the pulmonary veins (pv) is generally responsible for af recurrence in most cases. however, in a growing subset of patients undergoing repeat ablation for recurrent af, the pvs are chronically isolated and no other non-pv triggers of af can be identified. the investigators have previously shown that empirically ablating at known common non-pv trigger sites for af can improve arrhythmia free survival beyond pvi. the left atrial (la) posterior wall is also increasingly being isolated in af patients undergoing catheter ablation. however, long term arrhythmia free survival in af patients undergoing la posterior wall isolation is not consistently better than pvi alone. the objective of this study therefore is to assess whether performing empiric ablation of common non-pv trigger sites or achieving la posterior wall isolation can improve arrhythmia free survival in af patients who are undergoing repeat af ablation and in whom the pv remain chronically isolated and/or do not demonstrate af. the investigators propose to do this as prospective, randomized three arm study.

Eligibility criteria:
inclusion criteria: all patients undergoing first redo af ablation who have chronically isolated pulmonary veins and no non-pv triggers with provocation testing (randomized intra-procedure). exclusion criteria: 1. patients in whom ≥1 pvs have reconnected and af triggers can be elicited from the reconnected pv. 2. patients who demonstrated non-pv triggers for af. 3. patients who have experienced arrhythmia recurrence post ablation where the recurrent arrhythmia is other than atrial fibrillation or typical atrial flutter 4. failure to obtain informed consent 5. patients with a mechanical mitral valve

Keywords: pulmonary vein ablation repeat ablation posterior wall isolation
beta-cell transplantation in pre-uremic patients with type 1 diabetes

Conditions: Diabetes Mellitus, Type 1

Summary: to examine whether temporary immunosuppression with atg, tacrolimus and mmf allows prolonged survival of beta cell allografts in type 1 diabetic patients with early chronic complications of diabetes.


Eligibility criteria:
inclusion criteria: * type 1 insulin-dependent diabetic patients in relatively good general condition * non-smoker * body weight \< 80 kg * c-peptide \ 180 mg/dl) * ebv antibody positive * cooperative and reliable patient giving informed consent by signature; the patient should be informed in sufficient detail on the content and procedure of the protocol, indicating potential risks of intervention and of immunosuppressive therapy; the patient should also be informed that withdrawal of immunosuppressive therapy in patients with persistent plasma c-peptide positivity may result in subsequent loss of ß-cell graft function; the ß cell implant should be identified as a clinical trial exclusion criteria: * history of thrombosis or pulmonary embolism * abnormal liver function * hla antibodies

Keywords: diabetes mellitus, type 1 pancreatic beta cell transplantation
evaluating the safety and efficacy of ondansetron in the prevention of post endoscopic retrograde cholangiopancreatography pancreatitis

Conditions: Pancreatic Diseases

Summary: endoscopic retrograde cholangiopancreatography (ercp (, a key tool that is used in diagnosis and treatment of pancreato-biliary diseases. post-ercp pancreatitis (pep) is the most common and serious complication that can occur following this procedure and can lead to significant morbidity and mortality. a variety of patient-related and procedure-related factors have been associated with higher rates of pep.


Eligibility criteria:
inclusion criteria: 1. age more than 18 years old. 2. gender: males and females 3. patients with suitable indications for ercp due to suspected pancreato-biliary disorders. 4. blood amylase and lipase levels before ercp are within the normal limits. exclusion criteria: 1. age of less than18 years. 2. uncontrolled diabetes mellitus (dm) 3. severe bleeding tendency 4. impaired renal function (serum creatinine \> 2 mg/dl), (creatinine clearance \<30 ml/min) 5. patients with severe heart disease. 6. subjects who underwent prior biliary or pancreatic sphincterotomy or dilatation or stenting of either duct. 7. currently pregnant or nursing 8. admission due to established pancreatitis before ecrp 9. unwillingness to undergo ercp. 10. previously documented allergy to ondansetron.
home respiratory polygraphy in childhood sleep apnea-hypopnea syndrome (childsleep).

Conditions: Sleep Apnea; Home Respiratory Polygraphy Sleep Study; Childhood Sleep Apnea; Polysomnography; Therapeutic Decision

Summary: the aims of the study is to assess the diagnostic utility of home respiratory polygraphy (hrp) complemented with polysomnography (psg) in childhood obstructive sleep apnea-hypopnea syndrome (osas), as well as its usefulness in the therapeutic decisions. methods: children referred with suspected osas will be evaluated during one year performing home respiratory polygraphy in all cases. psg will be chosen in patients with concomitant pathology or according to medical criteria, or complemented with hrp in doubtful cases. clinical and anthropometric data, severity, technical quality and treatment will be obtained. patients will be divided in two groups (hrp vs psg) and compared, and the accuracy from hrp to establish a therapeutic decision it wil calculated. the investigator's hypothesis is that psg should be recommended only for complex or doubtful cases.


Eligibility criteria:
inclusion criteria: * sleep apnea suspicion exclusion criteria: * other sleep conditions * non valid home respiratory polygraphy and non valid polysomnography in the same patient * non informated consent

Keywords: childhood sleep apnea sleep apnea syndrome obstructive apnea syndrome obstructive apnea sleep
assessment of body image in patients with rheumatoid arthritis

Conditions: Body Image; Rheumatoid Arthritis

Summary: investigate body image of patients with rheumatoid arthritis, correlating with self-esteem, function and quality of life.

methods: forty-three ra patients and thirty-nine control patients between 18 and 70 years were evaluated. the ra group was made up of individuals with a diagnosis of ra and the control group was made up of individuals from the community, paired for gender, age and body mass index. the patients were assessed with regard to body image (body dysmorphic disorder examination (bdde)), self-esteem (rosenberg self-esteem scale), function (health assessment questionnaire (haq)) and quality of life (short form-36 (sf-36)).

Eligibility criteria:
inclusion criteria: * the ra group included patients between 18 and 70 years of age, of either gender, with an established diagnosis of ra based acr criteria and belonging to functional classes i, ii and iii. the control group was made up of individuals from the community paired for gender, age and body mass index with ra group. exclusion criteria: * individuals with fibromyalgia, neurological disease, psychiatric disorders or other severe co-morbidity were excluded from the study.

Keywords: body image rheumatoid arthritis
folate augmentation of treatment - evaluation for depression: a randomised controlled trial

Conditions: Depression

Summary: to determine whether giving folic acid to people with depression will help their antidepressants work better. if folate does help antidepressants to work better, then it will provide a safe, simple and cheap way of improving the treatment of depression.

clinical depression is common, debilitating and treatable; one in four people experience it during their lives. the majority of sufferers are treated in primary care and only half respond well to active treatment. evidence suggests that folate may be a useful adjunct to antidepressant treatment: 1) patients with depression often have a functional folate deficiency; 2) the severity of such deficiency, indicated by elevated homocysteine, correlates with depression severity, 3) low folate is associated with poor antidepressant response, and 4) folate is required for the synthesis of neurotransmitters implicated in the pathogenesis and treatment of depression. the primary objective of this multi-centred placebo-controlled randomised trial is to estimate the effect of folate augmentation in new or continuing treatment of depressive disorder in primary and secondary care. secondary objectives are to evaluate the cost-effectiveness of folate augmentation of antidepressant treatment, investigate how the response to antidepressant treatment depends on genetic polymorphisms relevant to folate metabolism and antidepressant response, and explore whether baseline folate status can predict response to antidepressant treatment. comparisons: eligible patients with moderate to severe depression will be randomised to receive 5mg of folic acid or placebo as an adjunct to their antidepressant treatment.

Eligibility criteria:
inclusion criteria: * only patients aged 18 or over * icd-10 diagnosis of moderate to severe depression * able to give informed consent (not delirious, actively psychotic or with severe communication or learning disability) * able to complete the research assessments exclusion criteria: * are folate deficient * are b12 deficient * have knowingly taken supplements containing folic acid within 2 months * suffer from psychosis * are already participating in another research project * are pregnant or planning to become pregnant * are taking anticonvulsants * have a serious, advanced or terminal illness with a life expectancy of less than 1 year * have recently started treatment for a medical condition which has not yet been stabilised * are taking lithium * have had a diagnosis or treatment for any malignant disease or any related condition such as intestinal polyposis

Keywords: depression folate folic acid antidepressants
tracheal intubation in patient with semi-rigid collar immobilization of the cervical spine: a comparison of fiberoptic bronchoscope assisted with pentax-airway scope and fiberoptic bronchoscope alone

Conditions: Cholecystitis

Summary: a semi-rigid cervical collar is recommended for immobilization of the cervical spine in patients with cervical spine injury. it has been suggested that a reduction in mouth opening is the major contributing factor to the deterioration in the glottic view obtained. fiberoptic intubation is among the most versatile techniques for managing both the anticipated and the unanticipated difficult airway. recently, combination of fiberoptic bronchoscope with videolaryngoscope has been suggested to permit visual control of the passage of the tube over the fibrescope into the laryngeal inlet. the aim of this study is to compare the intubation time and ease of intubation between fiberoptic bronchoscope alone and bronchoscope with pentax airwayscope.


Eligibility criteria:
inclusion criteria: * american society of anesthesiologist physical status class i, ii exclusion criteria: * uncontrolled or limited cardiovascular disease * abnormality of airway * necessity for rapid sequence induction * bmi \> 30
brain imaging in the diabetes prevention program outcomes study

Conditions: Alzheimer Disease

Summary: this is a cross-sectional pilot study of alzheimer's disease (ad) brain imaging biomarkers in diabetes prevention program (dpp) outcomes study (dppos) participants from the new york city sites (columbia and einstein), comparing 10 persons originally randomized to metformin and 10 persons randomized to placebo in dpp. all study procedures will be conducted at columbia university irving medical center. eligible participants will receive a pet scans and a brain mri, which may be conducted in one, two, or three separate visits.

hyperinsulinemia is believed to increase the risk of alzheimer's dementia through both cerebrovascular and a related mechanisms, and this hypothesis has prompted testing strategies related to hyperinsulinemia and diabetes in the prevention and treatment of alzheimer's dementia.these strategies usually entail improving insulin sensitivity to lower insulin and glucose levels, such as lifestyle (diet and exercise) and metformin, which were effective strategies for preventing diabetes in the dppos. there are conflicting data relating metformin with increased ad risk, and this needs to be clarified in dppos. several laboratory and human studies have suggested that metformin increases the risk of alzheimer's dementia, but this is countered by other studies indicating that it is beneficial. preliminary data in humans and animals support the beneficial effects of metformin on alzheimer's dementia risk.

Eligibility criteria:
inclusion criteria: * active participants in the diabetes prevention program outcomes study (dppos) in new york city originally randomized to metformin or placebo * 60 years and older exclusion criteria: * known dementia * contraindications to magnetic resonance imaging (mri) * contraindications to radio-contrast agents.

Keywords: metformin pre-diabetes type 2 diabetes dppos
staphylococcus aureus resistant to methicillin (mrsa) screening in trauma

Conditions: Emergencies

Summary: the main objective of this study and to know the incidence of healthy carriers of staphylococcus aureus resistant méti- patients supported for fracture of the proximal femur . this assessment will be made preoperatively by a nasal sampling and analysis through it by rapid polymerase chain reaction method genexpert® .

there are 85,000 fractures of the upper extremity in france each year. this is a frequent pathology in fragile patients. the characteristics in terms of comorbidities, age, sex and survival are well known from the literature. while secondary mechanical complications to surgery, hovering around 6 to 8%, mortality at one year is very high (around 25%). postoperative infection after a fracture of the upper end of the femur ranges from 2 to 8% depending on the series. this complication is responsible for morbidity and excess mortality linked to the need for revision surgery, prolongation of hospitalization and antibiotic treatment. in elective surgery, detection of staphylococcus aureus resistant to methicillin is systematic and recommended in many countries, preoperative level of the nasal cavity. parvizi then goya believe that this port increased from four to nine times the occurrence of infection at the surgical site. various epidemiological studies have shown the presence of staphylococcus aureus in over 30% of patients. this prevalence is lower in the french population. an estimated 70% the proportion of staphylococcus aureus in the periprosthetic infections, and 30% related specifically to the methicillin-resistant staphylococcus aureus. today there is no consensus on what to have vis-à-vis the detection of a hand and the other hand treatment of patients. the healthy carrier in the population overtake admitted to the trauma unit is unclear. it is therefore necessary to know these effects among patients with multiple pathologies. for methods of detection, the usual system and directed by swabbing and cultured with 90% sensitivity specificity of 100%. the demoyens existence of early detection as genexpert® cepheid® lets get this result is in an hour with a specificity of 98% and a sensitivity of 100%.

Eligibility criteria:
inclusion criteria: * patient treated in the trauma unit for fractures of the proximal femur belong to a social security scheme patient exclusion criteria: * minor patient * presence of abrasions * mrsa history * open fracture * ongoing infectious process * patients under judicial protection , guardianship * pregnant or breastfeeding women * patient refusal to participate in the study